X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs DR. DATSONS LABS - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE DR. DATSONS LABS CADILA HEALTHCARE/
DR. DATSONS LABS
 
P/E (TTM) x 20.1 -10.9 - View Chart
P/BV x 4.8 0.2 2,936.3% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 CADILA HEALTHCARE   DR. DATSONS LABS
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
DR. DATSONS LABS
Mar-14
CADILA HEALTHCARE/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs558126 444.3%   
Low Rs36231 1,169.9%   
Sales per share (Unadj.) Rs116.3133.0 87.4%  
Earnings per share (Unadj.) Rs17.90.2 11,785.3%  
Cash flow per share (Unadj.) Rs23.16.6 350.1%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs85.4128.8 66.3%  
Shares outstanding (eoy) m1,023.7431.66 3,233.5%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x4.00.6 671.9%   
Avg P/E ratio x25.7516.1 5.0%  
P/CF ratio (eoy) x19.911.8 167.8%  
Price / Book Value ratio x5.40.6 885.9%  
Dividend payout %19.60-   
Avg Mkt Cap Rs m470,6642,477 18,998.4%   
No. of employees `00011.8NA-   
Total wages/salary Rs m18,54556 33,116.1%   
Avg. sales/employee Rs Th10,072.7NM-  
Avg. wages/employee Rs Th1,569.1NM-  
Avg. net profit/employee Rs Th1,547.7NM-  
INCOME DATA
Net Sales Rs m119,0494,211 2,827.4%  
Other income Rs m1,13279 1,438.4%   
Total revenues Rs m120,1814,289 2,801.9%   
Gross profit Rs m28,475569 5,007.9%  
Depreciation Rs m5,388204 2,636.0%   
Interest Rs m911430 211.8%   
Profit before tax Rs m23,30813 183,527.6%   
Minority Interest Rs m6280-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6446 92,524.6%   
Profit after tax Rs m18,2925 381,083.3%  
Gross profit margin %23.913.5 177.1%  
Effective tax rate %24.248.0 50.4%   
Net profit margin %15.40.1 13,478.1%  
BALANCE SHEET DATA
Current assets Rs m82,0056,852 1,196.9%   
Current liabilities Rs m60,7206,711 904.8%   
Net working cap to sales %17.93.3 533.9%  
Current ratio x1.41.0 132.3%  
Inventory Days Days73161 45.5%  
Debtors Days Days98318 30.9%  
Net fixed assets Rs m83,7033,673 2,278.9%   
Share capital Rs m1,024317 323.4%   
"Free" reserves Rs m86,4213,761 2,297.8%   
Net worth Rs m87,4454,078 2,144.6%   
Long term debt Rs m25,5511,671 1,529.3%   
Total assets Rs m180,65312,633 1,430.1%  
Interest coverage x26.61.0 2,582.3%   
Debt to equity ratio x0.30.4 71.3%  
Sales to assets ratio x0.70.3 197.7%   
Return on assets %10.63.4 308.7%  
Return on equity %20.90.1 17,769.7%  
Return on capital %22.07.7 286.6%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m42,683964 4,427.7%   
Fx outflow Rs m11,242607 1,851.8%   
Net fx Rs m31,441357 8,809.5%   
CASH FLOW
From Operations Rs m9,1931,345 683.6%  
From Investments Rs m-9,737-2,256 431.7%  
From Financial Activity Rs m515-1,200 -42.9%  
Net Cashflow Rs m-29-2,111 1.4%  

Share Holding

Indian Promoters % 74.8 4.5 1,651.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.0 -  
FIIs % 5.9 1.4 437.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 94.1 11.7%  
Shareholders   44,069 20,807 211.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 19, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS